The AIT will be holding its AGM on Thursday 22nd October 2020 at 14:00 (UK time). Due to the global pandemic the AGM for 2020 will be a virtual webinar session.
If you would like to be sent the link to attend the AGM virtual webinar session please contact the Association of Inhalation Toxicologists <firstname.lastname@example.org> and your details will be added to the list (a link to the session will be sent out to you nearer the time). The Cisco Webex webinar session only allows 100 attendees so numbers will be limited however we do need our AIT members to attend if you possibly can.
Thankyou for your support of the AIT in these difficult times.
This is a final reminder for you to register for the AIT virtual Webinar series to be held 13th, 15th, 20th and 22nd October 2020 at 13:00 BST and to register to attend the Association of Inhalation Toxicologists Annual General Meeting to be held on 22nd October 2020 at 14:00 BST. Thanks to those who have already registered. We are looking forward to you joining us.
Below are the details of the 4 free Virtual Webinar Sessions the AIT will be hosting during October 2020 and the date for our virtual Annual General Meeting. We will be using Cisco WebEx platform to run the webinars and the presentation will be shared on screen.
Attending the webinars is free however with limited spaces registration in advance is essential. Once spaces are filled you will be added to a reserve list. Presenters please register for any of the other webinars you wish to attend. The spaces detailed below are as of 04 October 2020 and are subject to change.
If you have not already registered please email the AIT at email@example.com with details of the webinars you would like to attend. A registration email will then be sent out to you in due course for each webinar session.
This invite will be registered to your email account so cannot be shared with a third party.
Webinar 1: Tuesday 13th October 2020 – 50 minutes commencing at 13:00 BST
43 spaces remaining: closing date for registration is Sunday 11th October 2020
Title: Inhalation Delivery and SARS Preclinical Models. Presented by J. McDonald (Lovelace Biomedical).
Summary: Information on animal models designed to evaluate efficacy of intervention strategies in SARS-CoV-2, and considerations for treatment, endpoints and delivery, especially inhalation delivery. Presented by J. McDonald (Lovelace Biomedical).
Webinar 2: Thursday 15th October 2020 – 50 minutes commencing at 13:00 BST
45 spaces remaining: closing date for registration is Tuesday 13th October 2020
Title: Early De-risking Approaches for Identification of Anti-Fibrotics for Idiopathic Pulmonary Fibrosis (IPF) Treatment. Presented by C. Roper, M. McElroy and J. Aarbiou (Charles River Laboratories).
Abstract: Idiopathic Pulmonary Fibrosis (IPF) is a chronic lung disease leading to a progressive and irreversible decline in lung function caused by repetitive micro-injuries to the alveolar epithelium. To date, only nintedanib and pirfenidone have been licensed to treat IPF, therefore, there is an increased effort to discover new therapies. We have created a testing strategy for identifying new and improved therapies for IPF using in vitro and in vivo models. The strategy starts with the in vitro high throughput screening model, in vitro FMT Assay, followed by the low throughput 3D, EpiAlveolar model (which needs further optimization as it was developed for assessment of lung toxicity), and finally testing in the well established in vivo bleomycin model. This testing strategy provides an integrated (human in vitro and animal in vivo) testing program with 3Rs benefits. The in vitro FMT assay, the in vitro EpiAlveolar model assay and the in vivo bleomycins models will be discussed. In conclusion, human-derived in vitro models can be used to assess potency and toxicity of novel fibrotic compounds in disease relevant assays (e.g. FMT). Only compounds with the optimum potency and low toxicity will move forward into in vivo assays to assess exposure and efficacy. Integration of in vitro and in vivo data will improve with screening and selection for novel therapeutic anti-fibrotic drugs.
Webinar 3: Tuesday 20th October 2020 – 50 minutes commencing 13:00 BST
37 spaces remaining: closing date for registration is Sunday 18th October 2020
Title: Phase I: The transition from nonclinical to clinical and beyond. Presented by C. Laing (Covance).
Summary: An overview of first-in-human study designs. Focusing on how the non-clinical data are used to guide the study design, starting dose and dose escalations. How the emerging clinical data is used to adapt the study to better meet the objectives. And how a study can be expanded to increase the information obtained to assist the progression from first-in-human to proof of concept.
Webinar 4: Thursday 22nd October 2020 – 50 minutes commencing at 13:00 BST
16 spaces remaining: closing date for registration is Tuesday 20th October 2020
Title: Regulatory Toxicology: Safety Margin Assessments of Inhalation Drug Products. Presented by D. Jones (MHRA, UK) and L. Pei (FDA, US).
Summary: Safety margin assessments and recommendations in support of clinical development and registration of inhalation drug products (IDP) and non-IDP differ significantly. Key factors contributing to these differences include the following: the complexity and difficulty to test individual ingredients and formulations of IDP in nonclinical settings, difficulty to assess dosimetry and exposures of test articles (e.g., active pharmaceutical ingredients, excipients, and others) in both clinical and nonclinical settings, the complexity and uniqueness of inhalation toxicity studies in the laboratory animals, species differences in responses to inhaled materials, and the lack of effective monitoring of potential treatment-related responses in the lung in the clinical setting. These challenges can be further complicated when nonclinical programs are evaluated by regulatory scientists and their counterparts in the pharmaceutical industry and academia who lack expertise in inhalation toxicology and regulatory nonclinical safety evaluations. Regulatory scientists from the Medicines and Health Products Regulatory Agency (MHRA) of UK and US FDA will discuss in depth regulatory nonclinical safety evaluation of IDP and safety margin assessments in these two regions during the webinar.
The AIT looks forward to you joining us.
Visit - https://www.aitoxicology.org/ for more information on all of these webinars.